Xenon Pharmaceuticals (XENE) has released an update.
Xenon Pharmaceuticals highlighted their clinical data for XEN1101, a promising treatment for epilepsy and depression, at the American Academy of Neurology Annual Meeting. The presentations showcased interim results from a Phase 2b study and data on the drug’s efficacy based on disease severity. The company’s ongoing commitment to neuroscience and development of novel therapeutics was reinforced by these updates and their active engagement with neurologists at the event.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
